Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $29.8700 (-0.76%) ($29.8700 - $29.8700) on Tue. Sep. 14, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.55% (three month average) | RSI | 71 | Latest Price | $29.8700(-0.76%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.1% a day on average for past five trading days. | Weekly Trend | TGTX advances 6.6% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(69%) ARKG(65%) ARKK(60%) IBB(60%) IWO(60%) | Factors Impacting TGTX price | TGTX will decline at least -2.275% in a week (0% probabilities). VIXM(-46%) VXX(-39%) UUP(-19%) IGOV(-8%) UNG(-4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.275% (StdDev 4.55%) | Hourly BBV | -1.1 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $29.98(-0.37%) | 10 Day Moving Average | $29.73(0.47%) | 20 Day Moving Average | $27.39(9.05%) | To recent high | -26.2% | To recent low | 37.8% | Market Cap | $3.783b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |